SCHEMBL1839627

SCHEMBL1839627

Nc1nccc(-c2c[nH]c3nccc(N4Cc5ccccc5C4)c23)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 11/20 0.57
CDK5R1 Q15078 11/20 0.57
CCNT1 O60563 9/20 0.57
CDK9 P50750 9/20 0.57
CCNA2 P20248 8/20 0.57
CDK2 P24941 8/20 0.57
CCNA1 P78396 8/20 0.57
ROCK1 Q13464 9/20 0.56
CDC42BPB Q9Y5S2 9/20 0.56
ROCK2 O75116 8/20 0.56
PDPK1 O15530 2/20 0.52
CLK1 P49759 2/20 0.47
GSK3B P49841 2/20 0.47
DYRK1A Q13627 1/20 0.47
MAP3K14 Q99558 1/20 0.47
CCNB2 O95067 1/20 0.46
CDK1 P06493 1/20 0.46
HTR1A P08908 1/20 0.46
CCNB1 P14635 1/20 0.46
PRKACA P17612 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1838236 0.92 ROCK1 (0.54) CDK5CDK5R1CCNT1CDK9CCNA2
SCHEMBL2236999 0.84 ROCK1 (0.73) CDK5CDK5R1CCNT1CDK9CCNA2
SCHEMBL1837639 0.84 ROCK1 (0.60) CDK5CDK5R1CCNT1CDK9CCNA2
SCHEMBL1834620 0.84 ROCK1 (0.59) CDK5CDK5R1CCNT1CDK9CCNA2
SCHEMBL1839716 0.83 ROCK1 (0.75) CDK5CDK5R1CCNT1CDK9CCNA2
SCHEMBL1842497 0.83 ROCK1 (0.75) CDK5CDK5R1CCNT1CDK9CCNA2
SCHEMBL1841701 0.83 CDK5 (0.54) CDK5CDK5R1CCNT1CDK9CCNA2
SCHEMBL1841314 0.82 CDK2 (0.58) CDK5CDK5R1CCNT1CDK9CCNA2
SCHEMBL1839267 0.82 CDK2 (0.58) CDK5CDK5R1CCNT1CDK9CCNA2
SCHEMBL1839927 0.82 CDK2 (0.58) CDK5CDK5R1CCNT1CDK9CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2011526931-A 2011-10-20 JP claimed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US claimed
CN-102143746-A CDK modulators EXELIXIS INC 2011-08-03 CN claimed
EP-2320895-A2 CDK MODULATORS Exelixis, Inc. (US) 2011-05-18 EP claimed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 WO claimed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201599-A1 CDK Modulators CDK3, CDK1, CDKL1 CDK5 24/4885CDK5R1 41/4885CCNT1 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.